Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024Marine Maurel, Iván Martínez‐Baz, Ivan Mlinarić et al.|Eurosurveillance|2024Cited by 50
COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022Charlotte Lanièce Delaunay, Iván Martínez‐Baz, Noémie Sève et al.|Eurosurveillance|2024Cited by 11
COVID‐19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS‐CoV‐2 Infection Among Target Groups in Europe, October 2024–January 2025, VEBIS Primary Care NetworkCharlotte Lanièce Delaunay, Nuno Verdasca, Susana Monge et al.|Influenza and Other Respiratory Viruses|2025Cited by 10
Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24Esther Kissling, Marine Maurel, Francisco Pozo et al.|Eurosurveillance|2025Cited by 9
Exploring the effect of clinical case definitions on influenza vaccine effectiveness estimation at primary care level: Results from the end-of-season 2022–23 VEBIS multicentre study in EuropeMarine Maurel, Esther Kissling, Clara Mazagatos et al.|Vaccine|2024Cited by 7